Medgenics, Inc. Receives Notice of Allowance From the U.S. Patent Office for Claims That Expand IP for Its Platform Technology to Additional Therapeutic Proteins
4/22/2013 12:33:47 PM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of Biopump™, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced the United States Patent and Trademark Office has issued a Notice of Allowance of claims that expand the Company’s scope of patent coverage for additional therapeutic proteins. The claims in the patent are directed to a dermal Biopump expressing at least one recombinant gene product from any of the following: growth hormone, interferon beta, insulin, PDGF-BB, interleukin-1 receptor agonist (IL-1Ra), peptide YY3-36, interleukin-10 (IL-10) and G-CSF. These claims, combined with the prior grant of patents for genetically modified dermal micro-organ expression of erythropoietin and interferon alpha, broaden Medgenics’ scope of intellectual property in the field of genetically modified dermal micro-organs.
Help employers find you! Check out all the jobs and post your resume.